Small Extracellular Vesicles in Triple-Negative Breast Cancer: From Immune Checkpoint Modulation to Clinical Applications
- 14 May 2026
- journal article
- Published by American Chemical Society (ACS) in ACS Nano Medicine
- Vol. 1 (7) , 1575-1595
Abstract
Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer characterized by the absence of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). Among current treatment strategies, immune checkpoint inhibitor (ICI) therapy has shown promising clinical efficacy and is FDA-approved for TNBC. Immune checkpoints (ICPs) are regulatory proteins on immune cells that modulate immune responses to prevent overactivation and autoimmunity. Small extracellular vesicles (sEVs), a subtype of extracellular vesicles secreted by all cell types, mirror the molecular characteristics of their cells of origin. Tumor-derived sEVs can carry ICPs such as PD-L1, which interact with PD-1 on immune cells, mimicking the function of membrane-bound PD-L1 and contributing to immune evasion. sEVs derived from immune cells may carry ICPs like PD-1 and CTLA-4, potentially influencing immune responses and immunotherapy outcomes within the TNBC tumor microenvironment. Despite growing interest, the mechanisms by which ICP-bearing (ICP+) sEVs interact with immune and tumor cells in TNBC remain poorly understood. Existing reviews have explored ICPs and sEVs in cancer broadly, but few focus specifically on TNBC or the role of ICP+ sEVs in modulating its microenvironment. This review highlights the emerging role of ICP+ sEVs in TNBC progression, immune modulation, and immunotherapy resistance. We also examine their potential as biomarkers for disease monitoring and treatment response. Finally, we discuss future directions for ICP+ sEVs in clinical applications, including overcoming ICI therapy resistance in TNBC.Keywords
Funding Information
- Australian Government
- Macquarie University
This publication has 166 references indexed in Scilit:
- Extracellular vesicle surface display of αPD‐L1 and αCD3 antibodies via engineered late domain‐based scaffold to activate T‐cell anti‐tumor immunityJournal of Extracellular Vesicles, 2024
- Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approachesJournal of Extracellular Vesicles, 2024
- Microfluidics‐based molecular profiling of tumor‐derived exosomes for liquid biopsyView, 2023
- Manipulation of PD‐L1 Endosomal Trafficking Promotes Anticancer ImmunityAdvanced Science, 2022
- Sulfisoxazole Elicits Robust Antitumour Immune Response Along with Immune Checkpoint Therapy by Inhibiting Exosomal PD‐L1Advanced Science, 2021
- Engineered Cell‐Derived Vesicles Displaying Targeting Peptide and Functionalized with Nanocarriers for Therapeutic microRNA Delivery to Triple‐Negative Breast Cancer in MiceAdvanced Healthcare Materials, 2021
- Molecular evaluation of five different isolation methods for extracellular vesicles reveals different clinical applicability and subcellular originJournal of Extracellular Vesicles, 2021
- Therapeutic cooperation between auranofin, a thioredoxin reductase inhibitor and anti‐PD‐L1 antibody for treatment of triple‐negative breast cancerInternational Journal of Cancer, 2019
- CTLA-4 is constitutively expressed on tumor cells and can trigger apoptosis upon ligand interactionInternational Journal of Cancer, 2005
- Induced expression of PD‐1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death.The EMBO Journal, 1992